- Shares of thinly traded nano cap Trovagene (TROV -8.8%) continue their slide today on 4x higher volume. Prices have now cratered 66% from the $10.27 August 5 high.
- The company reported Q1 results earlier in the week. Notable by their absence are any revenues from its much-ballyhooed transrenal nucleic acid tests. It launched a BRAF test in its CLIA lab in October of last year and a KRAS test in March, but no revenues have been generated yet. Per its 10-Q, all of its $111K in revenues come from NPM1 royalties.
at Zacks.com (Nov 5, 2014)